Search results
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with...
telegraphherald.com· 6 days agoThe positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely
One of AbbVie's post-Humira hopefuls gets closer to clearing hurdle in Europe
Crain s Chicago Business· 5 days agoAbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster ...
I'm a cardiologist and I want women to stop doing these 6 things for their heart health
TODAY via Yahoo News· 5 days agoCardiologists look at all cholesterol values but especially your LDL, or “bad” cholesterol. Elevated...
Sotyktu and Cost: How to Find Savings and More
Healthline· 3 days agoTo find out how much you’ll pay for this medication, talk with your doctor, pharmacist, or insurance provider. Use a mail-order pharmacy to get your medication: Using a mail-order pharmacy might help lower your cost for Sotyktu.
California State Teachers Retirement System Acquires 42,587 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 3 days agoCalifornia State Teachers Retirement System raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form ...
AbbVie Inc. (NYSE:ABBV) Receives $176.14 Average PT from Brokerages
ETF DAILY NEWS· 2 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports.